Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.64 |
| ▸ | HTR1A | P08908 | 4/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.64 |
| ▸ | DRD3 | P35462 | 2/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | DRD1 | P21728 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.49 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 10/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Exaprolol SCHEMBL614255 | 0.88 | CYP1A2 (0.72) | CYP1A2CYP2D6SLC6A4HTR1AADRA1A | |
| Exaprolol SCHEMBL612844 | 0.87 | CYP1A2 (0.70) | CYP1A2CYP2D6SLC6A4HTR1AADRA1A | |
| SCHEMBL30295338 | 0.87 | CYP1A2 (0.73) | CYP1A2CYP2D6SLC6A4HTR1AADRA1A | |
| Exaprolol SCHEMBL614256 | 0.86 | CYP1A2 (0.69) | CYP1A2CYP2D6SLC6A4HTR1AADRA1A | |
| Procinolol SCHEMBL1254736 | 0.83 | CYP1A2 (0.67) | CYP1A2CYP2D6SLC6A4HTR1AADRA1A | |
| Exaprolol SCHEMBL11319783 | 0.83 | CYP1A2 (0.65) | CYP1A2CYP2D6SLC6A4HTR1AADRA1A | |
| SCHEMBL13148951 | 0.81 | HTR1A (0.75) | CYP1A2CYP2D6SLC6A4HTR1AADRA1A | |
| SCHEMBL8891641 | 0.79 | HTR1A (0.98) | CYP1A2CYP2D6SLC6A4HTR1AADRA1A | |
| SCHEMBL9233315 | 0.79 | HTR1A (0.68) | CYP1A2CYP2D6SLC6A4HTR1AADRA1A | |
| SCHEMBL7289148 | 0.79 | HTR1A (0.68) | CYP1A2CYP2D6SLC6A4HTR1AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6169105-B1 | POTENTIATING THE ACTION OF PAROXETINE IN INCREASING THE AVAILABILITY OF SEROTONIN, NOREPINEPHRINE AND DOPAMINE IN THE BRAIN BY ADMINISTERING PAROXETINE TO A PATIENT IN NEED THEREOF IN COMBINATION WITH WAY 100635 | ELI LILLY AND COMPANY | 2001-01-02 | — | — | US | disclosed |
| EP-0759299-B1 | Potentiation of serotonin response | LILLY CO ELI (US) | 2000-04-26 | — | — | EP | disclosed |
| US-5958429-A | TREATING DEPRESSION | ELI LILLY AND COMPANY (US) | 1999-09-28 | — | — | US | disclosed |
| US-5776969-A | MIXTURE OF ANTISEROTONIN AGENT AND SEROTONIN RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1997031629-A1 | TREATMENT OF SLEEP DISORDERS | ELI LILLY AND COMPANY (US) | 1997-09-04 | — | — | WO | disclosed |
| EP-0792649-A1 | Treatment of sleep disorders | ELI LILLY AND COMPANY (US) | 1997-09-03 | — | — | EP | disclosed |
| WO-1997006792-A1 | POTENTIATION OF SEROTONIN RESPONSE | ELI LILLY AND COMPANY (US) | 1997-02-27 | — | — | WO | disclosed |
| EP-0759299-A1 | Potentiation of serotonin response | ELI LILLY AND COMPANY (US) | 1997-02-26 | — | — | EP | disclosed |
| US-5552429-A | ADMINISTERING FLUOXETINE AND PINDOLOL TO INCREASE AVAILABILITY OF SEROTONIN, DOPAMINE AND NOREPINEPHRINE | ELI LILLY AND COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| US-5538992-A | SEROTONIN RECEPTOR ANTAGONIST AND FLUOXETINE FOR INCONTIENCE AND ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1996-07-23 | — | — | US | disclosed |
| US-5532264-A | POTENTIATION OF VENLAFAXINE, MILNACIPRAN AND DULOXETINE TO INCREASE AVAILABLE SEROTONIN, NOREPINEPHRINE AND DOPAMINE IN THE BRAIN BY ADMINISTERING OXYALKYLAMINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5532250-A | ADMINISTERING A SEROTONIN 1A RECEPTOR ANTAGONIST: ALPRENOLOL, PINDOLOL, PROPRANOLOL, OR TERTATOLOL, WITH FLUOXETINE, VENLAFAXINE, MILNACIPRAN RO DULOXETINE | ELI LILLY AND COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5532268-A | INCREASING THE SEROTONIN, NOREPINEPHRINE AND DOPAMINE IN THE BRAIN USING FLUOXETINE AND ALPRENOLOL, SPIPERONE, TETRATOLOL AND PROPRANOLOL | ELI LILLY AND COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5532244-A | Potentiation of drug response | ELI LILLY AND COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| EP-0714663-A2 | Potentiation of drug response by a serotonin 1A receptor antagonist | ELI LILLY AND COMPANY (US) | 1996-06-05 | — | — | EP | disclosed |
| EP-0687472-A2 | Potentiation of drug response by a serotonin 1A receptor antagonist | ELI LILLY AND COMPANY (US) | 1995-12-20 | — | — | EP | disclosed |
| EP-0642787-A2 | Cessation of tobacco use | ELI LILLY AND COMPANY (US) | 1995-03-15 | — | — | EP | disclosed |